Published in Exp Clin Cardiol on January 01, 2004
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (1998) 13.58
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 11.92
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell (1995) 11.72
Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem (1994) 10.75
PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature (1998) 10.09
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature (1998) 8.33
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell (1995) 7.99
Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology (1996) 7.92
PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell (1998) 7.91
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes (1998) 6.53
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A (1994) 6.46
PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med (2001) 6.09
Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell (1998) 5.78
A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell (2001) 5.76
Adipogenesis and obesity: rounding out the big picture. Cell (1996) 5.15
CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A (1997) 4.71
The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem (1997) 4.55
Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science (1996) 4.50
Activation of PPARgamma coactivator-1 through transcription factor docking. Science (1999) 4.33
Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature (1999) 4.32
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med (2001) 4.17
Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation (1998) 3.14
Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest (1997) 2.73
Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res (1998) 2.39
Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care (2003) 2.29
Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation (2000) 2.15
Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem (1999) 2.13
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation (2002) 2.12
Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem (1998) 2.02
Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest (1996) 1.78
Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol Endocrinol (1996) 1.75
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J (2002) 1.73
Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation (2000) 1.73
Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol (1999) 1.72
Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes (1997) 1.70
c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity. Endocrinology (1999) 1.60
Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem (1996) 1.57
Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res (1999) 1.57
Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation (1992) 1.53
Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest (1993) 1.51
Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J Neurochem (1998) 1.51
Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation (2001) 1.49
Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation (2003) 1.46
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun (2000) 1.43
Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. Gene Expr (1996) 1.42
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation (2002) 1.41
Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology (2001) 1.41
Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens (1996) 1.38
Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci (2000) 1.37
Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells. J Biol Chem (2000) 1.36
Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes (2000) 1.34
The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation. Mol Pharmacol (2002) 1.29
Thiazolidinedione-induced edema. Pharmacotherapy (2002) 1.27
p300 functions as a coactivator for the peroxisome proliferator-activated receptor alpha. J Biol Chem (1997) 1.27
Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol (2000) 1.26
Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J Pharmacol Exp Ther (2003) 1.24
Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun (2002) 1.21
Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol (2003) 1.20
Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res (1993) 1.16
Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. J Clin Invest (2000) 1.16
PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol (1999) 1.15
PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol (2002) 1.15
Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res (2000) 1.14
Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol (2000) 1.12
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension (2003) 1.09
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest (2003) 1.09
Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol (1996) 1.07
Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol (2003) 1.07
Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol (2001) 1.06
The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res (2003) 1.05
Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in rats. Redox Rep (2002) 1.05
Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol (2003) 1.05
Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis (2001) 0.97
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med (2001) 0.95
Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. Diabetologia (1992) 0.92
The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP. Biochem Biophys Res Commun (1997) 0.92
Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension. J Hypertens (1999) 0.88
Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia (2003) 0.87
Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes (1999) 0.87
Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells. Biochem Biophys Res Commun (1998) 0.84
The PPAR-gamma ligand 15-deoxy(delta12,14) prostaglandin J2 reduces the liver injury in endotoxic shock. Eur J Pharmacol (2003) 0.84
Menarini Academy Cardiovascular Research Awards in Basic Science 2001: ligands of the orphan receptor peroxisome-proliferator activator-gamma reduce myocardial infarct size. Med Sci Monit (2001) 0.83
GATA-6 is involved in PPARgamma-mediated activation of differentiated phenotype in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2003) 0.83
Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease. J Diabetes Complications (2002) 0.81
MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A (2010) 3.00
In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan). JACC Cardiovasc Interv (2010) 2.36
Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet (2011) 2.14
Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. JACC Cardiovasc Interv (2011) 2.12
Clinical impact of left ventricular outflow tract obstruction in takotsubo cardiomyopathy. Circ J (2015) 1.95
MicroRNA-1 and MicroRNA-133 in spontaneous myocardial differentiation of mouse embryonic stem cells. Circ J (2009) 1.93
The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest (2008) 1.89
Human and mouse adipose-derived cells support feeder-independent induction of pluripotent stem cells. Proc Natl Acad Sci U S A (2010) 1.88
Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J (2014) 1.64
MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J Am Heart Assoc (2012) 1.63
High blood viscosity is closely associated with cigarette smoking and markedly reduced by smoking cessation. Circ J (2010) 1.60
Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur J Heart Fail (2010) 1.54
Impact of J-CTO score on procedural outcome and target lesion revascularisation after percutaneous coronary intervention for chronic total occlusion: a substudy of the J-CTO Registry (Multicentre CTO Registry in Japan). EuroIntervention (2016) 1.53
Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med (2002) 1.52
Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol Cell Biol (2003) 1.45
Up-regulated expression of microRNA-143 in association with obesity in adipose tissue of mice fed high-fat diet. Biochem Biophys Res Commun (2008) 1.44
Aldehyde dehydrogenase 2 gene is a risk factor for myocardial infarction in Japanese men. Hypertens Res (2002) 1.43
Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients - Insight From the Fushimi AF Registry. Circ J (2015) 1.41
Acetylation of GATA-4 is involved in the differentiation of embryonic stem cells into cardiac myocytes. J Biol Chem (2005) 1.40
Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res (2010) 1.39
Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol (2008) 1.34
Light-induced structural changes in a putative blue-light receptor with a novel FAD binding fold sensor of blue-light using FAD (BLUF); Slr1694 of synechocystis sp. PCC6803. Biochemistry (2004) 1.33
Light-induced structural changes of apoprotein and chromophore in the sensor of blue light using FAD (BLUF) domain of AppA for a signaling state. Biochemistry (2005) 1.33
MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes. Biochem Biophys Res Commun (2009) 1.31
MicroRNA-15b modulates cellular ATP levels and degenerates mitochondria via Arl2 in neonatal rat cardiac myocytes. J Biol Chem (2009) 1.30
Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull (2011) 1.26
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol (2013) 1.23
MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat Commun (2013) 1.22
Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice. Cardiovasc Res (2010) 1.21
A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism (2012) 1.18
Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic Biol Med (2006) 1.18
Regulation of adipocyte differentiation by activation of serotonin (5-HT) receptors 5-HT2AR and 5-HT2CR and involvement of microRNA-448-mediated repression of KLF5. Mol Endocrinol (2010) 1.17
Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care (2012) 1.16
Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo. Circulation (2006) 1.14
Calcineurin-GATA-6 pathway is involved in smooth muscle-specific transcription. J Cell Biol (2002) 1.12
Autophagy limits acute myocardial infarction induced by permanent coronary artery occlusion. Am J Physiol Heart Circ Physiol (2011) 1.12
Orphan nuclear receptor Nur77 is involved in caspase-independent macrophage cell death. J Exp Med (2003) 1.11
Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol (2007) 1.11
MicroRNA-27a regulates beta cardiac myosin heavy chain gene expression by targeting thyroid hormone receptor beta1 in neonatal rat ventricular myocytes. Mol Cell Biol (2010) 1.09
Oxidative stress induces GLUT4 translocation by activation of PI3-K/Akt and dual AMPK kinase in cardiac myocytes. J Cell Physiol (2008) 1.07
Sirolimus-eluting stent for in-stent restenosis of left main coronary artery in takayasu arteritis. Circ J (2005) 1.06
Distinct characteristics of circulating vascular endothelial growth factor-a and C levels in human subjects. PLoS One (2011) 1.05
Rho/ROCK pathway contributes to the activation of extracellular signal-regulated kinase/GATA-4 during myocardial cell hypertrophy. J Biol Chem (2001) 1.05
Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. Mol Cancer (2013) 1.02
Tryptophan at position 104 is involved in transforming light signal into changes of beta-sheet structure for the signaling state in the BLUF domain of AppA. Plant Cell Physiol (2005) 1.01
Oxylipins arabidopsides C and D from Arabidopsis thaliana. J Nat Prod (2005) 1.00
Identification of p300-targeted acetylated residues in GATA4 during hypertrophic responses in cardiac myocytes. J Biol Chem (2008) 1.00
Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol (2013) 0.99
Comparison of three-year clinical outcomes after sirolimus-eluting stent implantation among insulin-treated diabetic, non-insulin-treated diabetic, and non-diabetic patients from j-Cypher registry. Am J Cardiol (2011) 0.99
Progranulin expression in advanced human atherosclerotic plaque. Atherosclerosis (2009) 0.98